$ADVM
Adverum Biotechnologies, Inc.

2018 Q3 Form 10-Q Financial Statement

#000156459018028654 Filed on November 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q3
Revenue $833.0K $463.0K
YoY Change 79.91% 17.22%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.830M $4.760M
YoY Change 1.47% -22.6%
% of Gross Profit
Research & Development $14.48M $10.27M
YoY Change 40.99% 22.85%
% of Gross Profit
Depreciation & Amortization $260.0K $530.0K
YoY Change -50.94% 15.22%
% of Gross Profit
Operating Expenses $24.31M $15.03M
YoY Change 61.67% 0.89%
Operating Profit -$14.57M
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.270M $742.0K
YoY Change 71.16% 253.33%
Pretax Income -$22.21M -$13.83M
YoY Change 60.59% -3.29%
Income Tax -$1.300M
% Of Pretax Income
Net Earnings -$20.96M -$13.83M
YoY Change 51.55% -3.3%
Net Earnings / Revenue -2515.97% -2986.83%
Basic Earnings Per Share
Diluted Earnings Per Share -$335.6K -$318.8K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $217.9M $186.6M
YoY Change 16.77% -19.33%
Cash & Equivalents $159.7M $31.71M
Short-Term Investments $58.20M $154.9M
Other Short-Term Assets $4.300M $2.900M
YoY Change 48.28% 3.57%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $222.2M $189.5M
YoY Change 17.26% -19.67%
LONG-TERM ASSETS
Property, Plant & Equipment $2.600M $3.300M
YoY Change -21.21% -23.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.100M $300.0K
YoY Change 266.67% 114.29%
Total Long-Term Assets $3.700M $8.700M
YoY Change -57.47% -57.97%
TOTAL ASSETS
Total Short-Term Assets $222.2M $189.5M
Total Long-Term Assets $3.700M $8.700M
Total Assets $225.9M $198.2M
YoY Change 13.98% -22.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.700M $1.600M
YoY Change 6.25% -48.39%
Accrued Expenses $7.800M $6.100M
YoY Change 27.87% 5.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.10M $9.600M
YoY Change 5.21% -9.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $300.0K $6.400M
YoY Change -95.31% -16.88%
Total Long-Term Liabilities $300.0K $6.400M
YoY Change -95.31% -16.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.10M $9.600M
Total Long-Term Liabilities $300.0K $6.400M
Total Liabilities $10.40M $17.20M
YoY Change -39.53% -15.27%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $215.6M $181.0M
YoY Change
Total Liabilities & Shareholders Equity $225.9M $198.2M
YoY Change 13.98% -22.76%

Cashflow Statement

Concept 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$20.96M -$13.83M
YoY Change 51.55% -3.3%
Depreciation, Depletion And Amortization $260.0K $530.0K
YoY Change -50.94% 15.22%
Cash From Operating Activities -$16.90M -$9.980M
YoY Change 69.34% 3.53%
INVESTING ACTIVITIES
Capital Expenditures -$270.0K -$190.0K
YoY Change 42.11% -47.22%
Acquisitions
YoY Change
Other Investing Activities $21.41M $2.810M
YoY Change 661.92%
Cash From Investing Activities $21.14M $2.620M
YoY Change 706.87% -827.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -20.00K -240.0K
YoY Change -91.67%
NET CHANGE
Cash From Operating Activities -16.90M -9.980M
Cash From Investing Activities 21.14M 2.620M
Cash From Financing Activities -20.00K -240.0K
Net Change In Cash 4.220M -7.600M
YoY Change -155.53% -24.0%
FREE CASH FLOW
Cash From Operating Activities -$16.90M -$9.980M
Capital Expenditures -$270.0K -$190.0K
Free Cash Flow -$16.63M -$9.790M
YoY Change 69.87% 5.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Small Business
EntitySmallBusiness
true
CY2018Q3 us-gaap Short Term Investments
ShortTermInvestments
58209000
CY2018Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
999000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159673000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1361000
us-gaap Share Based Compensation
ShareBasedCompensation
12250000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
15000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
353000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1388000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27825000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16815000
CY2018Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
5000000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
5000000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
15034000
us-gaap Operating Expenses
OperatingExpenses
62864000
us-gaap Operating Income Loss
OperatingIncomeLoss
-61322000
us-gaap Operating Income Loss
OperatingIncomeLoss
-43252000
us-gaap Operating Expenses
OperatingExpenses
44640000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14571000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
166000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41234000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33223000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
742000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3104000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1894000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41358000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1250000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1250000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-13829000
us-gaap Net Income Loss
NetIncomeLoss
-56968000
us-gaap Net Income Loss
NetIncomeLoss
-41358000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-102000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-442000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-56860000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41902000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.97
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43381000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
60856000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42849000
us-gaap Profit Loss
ProfitLoss
-56968000
us-gaap Profit Loss
ProfitLoss
-41358000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1592000
us-gaap Share Based Compensation
ShareBasedCompensation
6839000
advm Amortization Of Premium And Accrued Interest On Marketable Securities
AmortizationOfPremiumAndAccruedInterestOnMarketableSecurities
199000
advm Amortization Of Premium And Accrued Interest On Marketable Securities
AmortizationOfPremiumAndAccruedInterestOnMarketableSecurities
419000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-60000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-886000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1518000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
136000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-208000
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-25000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-884000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1388000
us-gaap Straight Line Rent
StraightLineRent
-233000
us-gaap Straight Line Rent
StraightLineRent
70000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
1250000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
55924000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
201038000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
117993000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
45061000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
652000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
918000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
61417000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-156895000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
70189000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
687000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
312000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1037000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
292000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
149000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
83000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
100000
us-gaap Repayments Of Debt
RepaymentsOfDebt
118000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
69970000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
103000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-442000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
90153000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-190457000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70519000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
222170000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
160672000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31713000
advm Unpaid Deferred Offering Costs In Accounts Payable And Accrued Expenses
UnpaidDeferredOfferingCostsInAccountsPayableAndAccruedExpenses
200000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
278000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
148000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates<font style="font-weight:normal;">&#8212; The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</font></p></div>
CY2017Q4 advm Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0
CY2017Q4 advm Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
0
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
183000
CY2018Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-07-17
dei Entity Information Date To Change Former Legal Or Registered Name
EntityInformationDateToChangeFormerLegalOrRegisteredName
2016-05-11
CY2018Q3 advm Cash And Cash Equivalent Amortized Cost
CashAndCashEquivalentAmortizedCost
158368000
CY2018Q3 advm Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0
CY2018Q3 advm Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
0
CY2018Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
158368000
CY2018Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
58261000
CY2018Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
52000
CY2018Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
58209000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2295000
CY2018Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2852000
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2359000
CY2018Q3 advm Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Temporary
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxTemporary
100000
CY2018Q3 advm Other Than Temporary Impaired Investments Available For Sale Securities
OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities
0
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2259000
CY2018Q3 advm Accrued Preclinical Clinical And Development Process Costs
AccruedPreclinicalClinicalAndDevelopmentProcessCosts
1973000
CY2017Q4 advm Accrued Preclinical Clinical And Development Process Costs
AccruedPreclinicalClinicalAndDevelopmentProcessCosts
2165000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
593000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
245000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
294000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3344000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4221000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4683000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
4846000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
33853000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
51241000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6695000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1709000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1596000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
520000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6288000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3016000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.51
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.29
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.43
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.05
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.90
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.83
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13001000
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7745000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2996000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2700000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12250000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6839000
advm Number Of Executives Departure
NumberOfExecutivesDeparture
2
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9100000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10000000

Files In Submission

Name View Source Status
0001564590-18-028654-index-headers.html Edgar Link pending
0001564590-18-028654-index.html Edgar Link pending
0001564590-18-028654.txt Edgar Link pending
0001564590-18-028654-xbrl.zip Edgar Link pending
advm-10q_20180930.htm Edgar Link pending
advm-20180930.xml Edgar Link completed
advm-20180930.xsd Edgar Link pending
advm-20180930_cal.xml Edgar Link unprocessable
advm-20180930_def.xml Edgar Link unprocessable
advm-20180930_lab.xml Edgar Link unprocessable
advm-20180930_pre.xml Edgar Link unprocessable
advm-ex101_154.htm Edgar Link pending
advm-ex102_155.htm Edgar Link pending
advm-ex311_11.htm Edgar Link pending
advm-ex312_12.htm Edgar Link pending
advm-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gwgmn3hl4slz000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending